EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AZD 1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia‐mediated neuroinflammation and ischemic brain injury

Zhen Lan, Long-Jie Qu, Ying Liang, Li-Qiu Chen, Shuai Xu, Jian-Wei Ge iD, Zhi-Wei Xue, Xin-Yu Bao, Sheng-Nan Xia, Hai-Yan Yang, Jing Huang, Yun Xu iD und 1 weitere

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.14696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Zhen Lan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Microglia, Neuroinflammatory Diseases, Pyridines, Quinolones. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Province Key Medical Discipline, National Science and Technology Innovation 2030 - Major projects of "Brain Science and Brain-Like Research", Nanjing Medical Science and Technology Development Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Excessive neuroinflammation mediated mainly by microglia plays a crucial role in ischemic stroke. AZD1390, an ataxia telangiectasia mutated (ATM) specific inhibitor, has been shown to promote radio‐sensitization and survival in central nervous system malignancies, while the role of AZD1390 in ischemic stroke remains unknown.

Methods

Real‐time PCR, western blot, immunofluorescence staining, flow cytometry and enzyme‐linked immunosorbent assays were used to assess the activation of microglia and the release of inflammatory cytokines. Behavioral tests were performed to measure neurological deficits. 2,3,5‐Triphenyltetrazolium chloride staining was conducted to assess the infarct volume. The activation of NF‐κB signaling pathway was explored through immunofluorescence staining, western blot, co‐immunoprecipitation and proximity ligation assay.

Results

The level of pro‐inflammation cytokines and activation of NF‐κB signaling pathway was suppressed by AZD1390 in vitro and in vivo. The behavior deficits and infarct size were partially restored with AZD1390 treatment in experimental stroke. AZD1390 restrict ubiquitylation and sumoylation of the essential regulatory subunit of NF‐κB (NEMO) in an ATM‐dependent and ATM‐independent way respectively, which reduced the activation of the NF‐κB pathway.

Conclusion

AZD1390 suppressed NF‐κB signaling pathway to alleviate ischemic brain injury in experimental stroke, and attenuated microglia activation and neuroinflammation, which indicated that AZD1390 might be an attractive agent for the treatment of ischemic stroke.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicrogliaNeuroinflammatory DiseasesPyridinesQuinolonesAnimalsMaleMiceMice, Inbred C57BLBrain IschemiaAtaxia Telangiectasia Mutated ProteinsNF-kappa BCytokinesSignal Transduction

Stichwörter der Autor:innen

ATM inhibitorAZD1390NF‐κB pathwayischemic strokemicroglianeuroinflammation

Substanzen

Ataxia Telangiectasia Mutated ProteinsNF-kappa BCytokinesAZD1390PyridinesQuinolones

Autor:innen und Institutionen

  • Department of Neurology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Neurology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
  • Department of Neurology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
  • State Key Laboratory of Pharmaceutical Biotechnology and Institute of Translational Medicine for Brain Critical Diseases, Nanjing University, Nanjing, Jiangsu, China.
  • Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China.
  • Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, Jiangsu, China.

ORCID-Profile: Jian-Wei Ge, Yun Xu, Xiao-Lei Zhu

Förderung

  • Jiangsu Province Key Medical Discipline
  • National Science and Technology Innovation 2030 - Major projects of "Brain Science and Brain-Like Research"
  • Nanjing Medical Science and Technology Development Foundation
  • Key Research and Development Program of Jiangsu Province of China

Zitieren

APA

Lan, Z., Qu, L. J., Liang, Y., Chen, L. Q., Xu, S., Ge, J. W., Xue, Z. W., Bao, X. Y., Xia, S. N., Yang, H. Y., Huang, J., Xu, Y., & Zhu, X. L. (2024). AZD 1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia‐mediated neuroinflammation and ischemic brain injury. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14696

Vancouver

Lan Z, Qu LJ, Liang Y, Chen LQ, Xu S, Ge JW, et al. AZD 1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia‐mediated neuroinflammation and ischemic brain injury. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14696

BibTeX
@article{Lan2024,
  author = {Lan, Zhen and Qu, Long-Jie and Liang, Ying and Chen, Li-Qiu and Xu, Shuai and Ge, Jian-Wei and Xue, Zhi-Wei and Bao, Xin-Yu and Xia, Sheng-Nan and Yang, Hai-Yan and Huang, Jing and Xu, Yun and Zhu, Xiao-Lei},
  title = {AZD 1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia‐mediated neuroinflammation and ischemic brain injury},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.14696}
}
Kostenlos starten →